Back to Search
Start Over
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial
- Source :
- The Lancet Respiratory Medicine; February 2020, Vol. 8 Issue: 2 p147-157, 11p
- Publication Year :
- 2020
-
Abstract
- At present, no approved pharmacotherapies are available for unclassifiable interstitial lung disease (ILD), which is characterised by progressive fibrosis of the lung. We aimed to assess the efficacy and safety of pirfenidone in patients with progressive fibrosing unclassifiable ILD.
Details
- Language :
- English
- ISSN :
- 22132600 and 22132619
- Volume :
- 8
- Issue :
- 2
- Database :
- Supplemental Index
- Journal :
- The Lancet Respiratory Medicine
- Publication Type :
- Periodical
- Accession number :
- ejs52343910
- Full Text :
- https://doi.org/10.1016/S2213-2600(19)30341-8